MedWatch

Bavarian-CEO: ”Yellow fever, hepatitis, you name it”

Bavarian Nordic’s development contract with the US authorities gives the CEO of the company hope that its vaccine technology can be expanded to diseases with a greater commercial potential.

Foto: PR, Bavarian Nordic

Earlier today Bavarian Nordic announced it had signed a contract with the US government, the aim of which it is to examine if the company’s vaccine technology can be used against other diseases. According to CEO Anders Hedegaard the deal is a direct consequence of a year-long collaboration with the Americans concerning the company’s technology.

“This is an extension of the many discussions we have had concerning a number of other areas of collaboration. Aside from being used for the smallpox vaccine, our technology also has the potential to be utilized in other areas. The Americans have had an interest in - and a dialogue with us about - how a development program could be initiated and now we have done just that.”

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Dansk Biotek skifter navn

Den danske brancheorganisation for biotekselskaber, Dansk Biotek, skifter navn til "Danish Bio - Dansk Biotek" for at imødekomme den stigende internationalisering af branchen, fortæller formand.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier